By Staff writer
Largest Emirati pharmaceutical company announces plans to launch Saudi operations in coming months
Julphar, the largest Emirati pharmaceutical company, has announced sales revenue of AED759.7 million in the first half of 2016.
The company said it posted a gross profit of AED465.7 million while its net profit for the period was AED133.8 million ($36.2 million).
Dr Ayman Sahli, CEO at Julphar said in comments published by news agency WAM: "We have accomplished significant progress. We have launched the real-time continuous glucose monitoring device (CGM), Dexcom G4 Platinum in Jordan, and as part of our commitment to contribute to a better healthcare in the region, we have launched new products in our targeted markets."
These include the general inhalational anesthetic Sojourn in Saudi Arabia, MEBO Scar in Algeria and the new Proton Pump Inhibitor Pantonix tablets in the UAE.
Sahli added: "Our divisions are also moving forward, as per Julphar’s ambition to drive for continuous improvement."
In June, Julphar Bangladesh has received the ISO certification from the Bangladesh Accreditation Board, demonstrating the company’s ability to provide medicines that meet and comply with international standards and regulatory requirements while Julphar Saudi Arabia’s operations are expected to launch in the coming months.